Although we would basically agree that eosinopenia may play some roles in clinical progression of COVID-19,1 the very modest difference found in COVID-19 patients with or without severe illness and the current technical drawbacks in measuring eosinophils in whole blood would persuade us that routine assessment of this parameter remains questionable in patients with COVID-19. Until the functional sensitivity and the analytical imprecision of the modern hematological analyzers will be improved, relying on the eosinophil count for therapeutic management of COVID-19 would hence remain largely unwarranted.
Eosinophil count in coronavirus disease 2019: more doubts than answers
Lippi, Giuseppe
;
2021-01-01
Abstract
Although we would basically agree that eosinopenia may play some roles in clinical progression of COVID-19,1 the very modest difference found in COVID-19 patients with or without severe illness and the current technical drawbacks in measuring eosinophils in whole blood would persuade us that routine assessment of this parameter remains questionable in patients with COVID-19. Until the functional sensitivity and the analytical imprecision of the modern hematological analyzers will be improved, relying on the eosinophil count for therapeutic management of COVID-19 would hence remain largely unwarranted.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.